Tesaro, Inc.

This large, late-stage study is testing whether adding two newer drugs (dostarlimab and niraparib) to standard chemotherapy works better than standard care alone for women newly diagnosed with advanced ovarian cancer. The main goal is to see if the new combination can keep the ca…

This large Phase 3 study is testing whether adding the immunotherapy drug dostarlimab to standard chemotherapy helps women with advanced or recurrent endometrial cancer live longer and keeps their cancer from progressing. The trial involves 785 participants who are randomly assig…

This study tested whether taking the drug niraparib as ongoing 'maintenance' therapy could help keep advanced ovarian cancer from returning after successful initial chemotherapy. It involved 733 women with Stage III or IV ovarian cancer who had responded well to their first round…

This is the first study in people to test a new immunotherapy drug called TSR-022. The main goals are to find a safe dose and see if the drug can help shrink tumors in adults with advanced cancers that have spread. The study will test TSR-022 by itself and combined with other can…

This is the first study in humans of an experimental immunotherapy drug called dostarlimab for people with advanced solid tumors that have stopped responding to available treatments. The main goal is to find a safe dose and schedule for the drug and to check for early signs that …